midecamycin A1

Mb-6 (midecamycin A1) is a primary active metabolite of miokamycin (also known as midecamycin acetate), a 16-membered macrolide antibiotic developed by Meiji Seika Pharma. As a metabolite, Mb-6 is formed through the deacetylation of the parent drug in the liver and gastrointestinal tract. It retains significant antimicrobial activity and is considered a major contributor to the therapeutic efficacy of miokamycin in treating various bacterial infections. Mb-6 exerts its effect by binding to the 50S ribosomal subunit of bacteria, specifically interacting with the 23S rRNA to inhibit protein synthesis by blocking the exit tunnel of the nascent peptide chain. Toxicological studies have indicated that Mb-6 has a favorable safety profile with low systemic toxicity.

Other names

midecamycinmiokamycin metabolite Mb-69,3"-di-O-deacetylmiokamycin